Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19610270 | 0.95 | GPR119 (0.61) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL6189661 | 0.92 | GPR119 (0.58) | GPR119CHEK2ALDH1A1USP30PDE4B | |
| SCHEMBL2735422 | 0.89 | GPR119 (0.67) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL12533230 | 0.89 | GPR119 (0.67) | GPR119CHEK2ALDH1A1PDE4APDE4B | |
| SCHEMBL264162 | 0.89 | GPR119 (0.67) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL2116540 | 0.88 | GPR119 (0.65) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL2793124 | 0.88 | GPR119 (0.65) | GPR119CHEK2ALDH1A1HRH3 | |
| SCHEMBL3073527 | 0.88 | GPR119 (0.65) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL2366151 | 0.88 | GPR119 (0.65) | GPR119CHEK2ALDH1A1USP30HRH3 | |
| SCHEMBL5268593 | 0.87 | GPR119 (0.65) | GPR119CHEK2ALDH1A1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| CN-109641918-B | Imidazoles as inhibitors of histone demethylases | 欧洲肿瘤研究所有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-20 | — | — | US | disclosed |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-03-30 | — | — | US | disclosed |
| EP-3458460-B1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-12-09 | — | — | EP | disclosed |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-24 | — | — | US | disclosed |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-17 | — | — | US | disclosed |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-02-18 | — | — | US | disclosed |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2019-05-23 | — | — | US | disclosed |
| EP-2964613-B1 | H3 ANTAGONISTS CONTAINING PHENOXYPIPERIDINE CORE STRUCTURE | RICHTER GEDEON NYRT (HU) | 2018-07-18 | — | — | EP | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | KDM1B, KDM1A, INMT | GPR119 123/4885CHEK2 1541/4885ALDH1A1 245/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GPR119 658/4885CHEK2 4167/4885ALDH1A1 355/4885 |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, INMT | GPR119 123/4885CHEK2 1541/4885ALDH1A1 245/4885 |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | GPR119 2077/4885CHEK2 4397/4885ALDH1A1 528/4885 |
| US-20190152987-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, DOT1L | GPR119 274/4885CHEK2 1643/4885ALDH1A1 229/4885 |
| US-20200299303-A1 | IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS | DOT1L, KDM1B, KDM1A | GPR119 382/4885CHEK2 1402/4885ALDH1A1 334/4885 |
| US-10562914-B2 | Imidazoles as histone demethylase inhibitors | KDM1B, KDM1A, DOT1L | GPR119 274/4885CHEK2 1643/4885ALDH1A1 229/4885 |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | GPR119 1759/4885CHEK2 1002/4885ALDH1A1 319/4885 |
| US-10961255-B2 | Imidazoles as histone demethylase inhibitors | DOT1L, KDM1B, KDM1A | GPR119 382/4885CHEK2 1402/4885ALDH1A1 334/4885 |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | GPR119 741/4885CHEK2 4539/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.